Research programme: MicAbody antibodies - Xyphos

Drug Profile

Research programme: MicAbody antibodies - Xyphos

Alternative Names: MicAbody™ proteins - Xyphos

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AvidBiotics Corp.
  • Developer Xyphos
  • Class Antibodies; Antineoplastics; Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Cytomegalovirus infections

Most Recent Events

  • 01 Nov 2017 AvidBiotics splits itself into two companies, Xyphos to Develop Cell-based Therapeutics for Cancer and Pylum Biosciences that will focus on antibacterial proteins for microbiota management and drug-resistant bacteria
  • 12 Sep 2017 Early research in Cytomegalovirus infections in USA before September 2017 (AvidBiotics pipeline, September 2017)
  • 12 Sep 2017 Preclinical trials in Cancer in USA before September 2017 (AvidBiotics pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top